33 research outputs found

    Engineering Options for the U.S. Fusion Demo *

    Get PDF
    ABSTRACT Through its successful operation, the U.S. Fusion Demo must be sufficiently convincing that a utility or independent power producer will choose to purchase one as its next electric generating plant. A fusion power plant which is limited to the use of currently-proven technologies is unlikely to be sufficiently attractive to a utility unless fuel shortages and regulatory restrictions are far more crippling to competing energy sources than currently anticipated. In that case, the task of choosing an appropriate set of engineering technologies today involves trade-offs between attractiveness and technical risk. The design space for an attractive tokamak fusion power core is not unlimited; previous studies have shown that advanced lowactivation ferritic steel, vanadium alloy, or SiC/SiC composites are the only candidates we have for the primary in-vessel structural material. An assessment of engineering design options has been performed using these three materials and the associated in-vessel component designs which are compatible with them

    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

    Get PDF
    Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1–2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96–1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09–5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08–2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments

    Princeton Plasma Physics Laboratory Modular Coil Design for the Ultra-low Aspect Ratio Quasi-axially Symmetric Stellarator MHH2 PRINCETON PLASMA PHYSICS LABORATORY PPPL PPPL-4107 PPPL-4107 PPPL Report Disclaimers Full Legal Disclaimer Trademark Disclaimer

    No full text
    Abstract-A family of two field-period quasi-axisymmetric stellarators generally known as MHH2 with aspect ratios of only ~2.5 was found. These configurations have low field ripples and excellent confinement of α particles. This discovery raises the hope that a compact stellarator reactor may eventually be designed with the property of tokamak transport and stellarator stability. In this paper we demonstrate that smooth modular coils may be designed for this family of configurations that not only yield plasmas with good physics properties but also possess engineering properties desirable for compact power producing reactors. We show designs featuring 16 modular coils with ratios of major radius to minimum coil-plasma separation ~5.5, major radius to minimum coil-coil separation ~10 and the maximum field in coil bodies to the field on axis ~2 for 0.2 m 2 conductors. These coils is expected to allow plasmas operated at 5% β with α energy loss < 10% for a reactor of major radius <9 m at 5 T
    corecore